Revenue, last year
€9M
−55.2% vs prior year
Net income
−€49.2M
+0.6% vs prior year
EPS, diluted
−€0.55
+9.8% vs prior year
Operating cash flow
−€52.8M
−665% vs prior year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | €9M | −€49.2M |
| FY24 | €20.1M | −€49.5M |
| FY23 | €61.6M | −€7.6M |
| FY22 | €57.7M | −€58.1M |
| FY21 | €24.7M | −€52.8M |
| FY20 | €69.8M | −€64M |
| FY19 | €85.4M | −€20.8M |
| FY18 | €94M | €3M |
| FY17 | €44M | −€48.4M |
| FY16 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −599.8% | −546.1% |
| FY24 | −256.3% | −245.9% |
| FY23 | −20.6% | −12.3% |
| FY22 | −99.6% | −100.7% |
| FY21 | −193.6% | −213.8% |
| FY20 | 1.5% | −91.7% |
| FY19 | 1.8% | −24.3% |
| FY18 | 5.5% | 3.2% |
| FY17 | −90.8% | −109.9% |
| FY16 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −€52.9M |
| FY24 | −€7.3M |
| FY23 | −€32.9M |
| FY22 | −€19.7M |
| FY21 | −€59.4M |
| FY20 | −€52.7M |
| FY19 | €33.7M |
| FY18 | −€33.4M |
| FY17 | −€51M |
| FY16 | - |
- Innate Pharma
- Healthcare median
Show the numbers
| Year | Innate Pharma | Healthcare median |
|---|---|---|
| FY25 | −546.1% | −30.6% |
| FY24 | −245.9% | −47% |
| FY23 | −12.3% | −58% |
| FY22 | −100.7% | −80.4% |
| FY21 | −213.8% | −71.8% |
| FY20 | −91.7% | −62.2% |
| FY19 | −24.3% | −46.2% |
| FY18 | 3.2% | −49.6% |
| FY17 | −109.9% | −45.9% |
| FY16 | - | −36% |